The research company Chosa Oncology reports new data that confirm the clinical relevance of the biomarker Platin-DRP, now also on NanoString’s transcriptomic platform, where the analysis predicts overall survival with statistical significance in patients with non-small cell lung cancer treated with platinum-based chemotherapy.The results build on earlier findings from the SPLENDOUR study, which showed that Platin-DRP robustly predicts benefit from both carboplatin and cisplatin treatment. The new analysis shows high correlation with the original signature and means that the addressable market doubles because the biomarker now works across two technology platforms.